Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma | Zendy

Sandra P. D’Angelo | Zendy; Jeffery S. Russell | Zendy; Célèste Lebbé | Zendy; Bartosz Chmielowski | Zendy; Thilo Gambichler | Zendy; JeanJacques Grob | Zendy; Felix Kiecker | Zendy; Guilherme Rabinowits | Zendy; Patrick Terheyden | Zendy; Isabella Zwiener | Zendy; Marcis Bajars | Zendy; Meliessa Hennessy | Zendy; Howard L. Kaufman | Zendy

AI Assistant Blog Pricing

Open Access

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma

Author(s) -

Sandra P. D’Angelo,

Jeffery S. Russell,

Célèste Lebbé,

Bartosz Chmielowski,

Thilo Gambichler,

JeanJacques Grob,

Felix Kiecker,

Guilherme Rabinowits,

Patrick Terheyden,

Isabella Zwiener,

Marcis Bajars,

Meliessa Hennessy,

Howard L. Kaufman

Publication year - 2018

Publication title -

jama oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 8.846

H-Index - 99

eISSN - 2374-2445

pISSN - 2374-2437

DOI - 10.1001/jamaoncol.2018.0077

Subject(s) - merkel cell carcinoma , avelumab , medicine , merkel cell polyomavirus , tolerability , merkel cell , clinical endpoint , response evaluation criteria in solid tumors , oncology , skin cancer , progressive disease , carcinoma , clinical trial , adverse effect , cancer , immunotherapy , chemotherapy , nivolumab

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog